Skip to main content
. 2014 Dec 11;15(12):22960–22977. doi: 10.3390/ijms151222960

Figure 1.

Figure 1

Scheme of encapsulation of doxorubicin into (A) the liposome modified by cholesterol and (B) apoferritin. (C) Size distribution of liposome and (D) microphotography of liposomes. Liposomes are highlighted with a circle (red circle = 100 nm and orange circle = 200 nm); (E) Size distribution of apoferritin. Absorbtion spectra in the range 230–800 nm of (F) 100 µg/mL Myocet; (G) Epirubicin; (H) Liposome (a), Doxorubicin (b), Encapsulated Doxorubicin into the liposome (c); (I) Apoferritin (a), Doxorubicin (b), Encapsulated Doxorubicin into the apoferritin (c); Emission spectra in the range 520–820 nm of (J) 100 µg/mL Myocet; (K) Epirubicin; (L) Liposome (a), Doxorubicin (b), Encapsulated Doxorubicin into the liposome (c); (M) Apoferritin (a), Doxorubicin (b), Encapsulated Doxorubicin into the apoferritin (c). The excitation wavelength was 510 nm.